|
US6811779B2
(en)
|
1994-02-10 |
2004-11-02 |
Imclone Systems Incorporated |
Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
|
|
US6395733B1
(en)
*
|
1995-06-07 |
2002-05-28 |
Pfizer Inc |
Heterocyclic ring-fused pyrimidine derivatives
|
|
US7060808B1
(en)
*
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
ES2297864T3
(es)
|
1996-08-23 |
2008-05-01 |
Novartis Ag |
Pirrolopirimidinas sustituidas y procesos para su preparacion.
|
|
EP0929553B1
(en)
|
1996-10-02 |
2005-03-16 |
Novartis AG |
Pyrimidine derivatives and processes for the preparation thereof
|
|
BR9814458A
(pt)
|
1997-09-02 |
2001-10-23 |
Du Pont Pharm Co |
Composto, composição farmacêutica e método de tratamento de disfunções afetivas
|
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
|
ES2356886T3
(es)
|
1998-03-31 |
2011-04-14 |
Kyowa Hakko Kirin Co., Ltd. |
Compuestos heterocíclicos nitrogenados.
|
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
PA8474101A1
(es)
*
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
|
AU3951899A
(en)
|
1998-06-19 |
2000-01-05 |
Pfizer Products Inc. |
Pyrrolo(2,3-d)pyrimidine compounds
|
|
HUP0201480A3
(en)
*
|
1999-05-14 |
2009-03-30 |
Imclone Systems Inc |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
|
ATE380031T1
(de)
|
1999-12-10 |
2007-12-15 |
Pfizer Prod Inc |
Pyrrolo 2,3-d pyrimidinderivate enthaltende zusammensetzungen
|
|
WO2001096336A2
(en)
|
2000-06-14 |
2001-12-20 |
Warner-Lambert Company |
6,5-fused bicyclic heterocycles
|
|
CA2412560C
(en)
|
2000-06-26 |
2008-12-30 |
Pfizer Products Inc. |
Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
|
|
AU2001295002B2
(en)
*
|
2000-08-09 |
2007-05-31 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
KR100875380B1
(ko)
*
|
2001-06-23 |
2008-12-23 |
아벤티스 파마슈티칼스 인크. |
단백질 키나제 억제제로서의 피롤로피리미딘
|
|
EP1441736A2
(en)
*
|
2001-10-29 |
2004-08-04 |
Novartis AG |
Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
|
|
CA2507392A1
(en)
|
2002-11-26 |
2004-06-10 |
Pfizer Products Inc. |
Method of treatment of transplant rejection
|
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
|
WO2004093812A2
(en)
*
|
2003-04-22 |
2004-11-04 |
Irm Llc |
Compounds that induce neuronal differentiation in embryonic stem cells
|
|
BRPI0411250A
(pt)
|
2003-06-09 |
2006-08-29 |
Samuel Waksal |
método de inibição de receptor tirosina cinase com um antagonista extracelular e um antagonista intracellular
|
|
US20050165029A1
(en)
*
|
2004-01-13 |
2005-07-28 |
Ambit Biosciences Corporation |
Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
|
|
GB0403606D0
(en)
|
2004-02-18 |
2004-03-24 |
Novartis Ag |
Organic compounds
|
|
PT1735348E
(pt)
|
2004-03-19 |
2012-07-24 |
Imclone Llc |
Anticorpo anti-receptor do factor de crescimento humano
|
|
CA2564953A1
(en)
*
|
2004-05-03 |
2005-11-24 |
Janssen Pharmaceutica N.V. |
Novel indole derivatives as selective androgen receptor modulators (sarms)
|
|
TW200615268A
(en)
*
|
2004-08-02 |
2006-05-16 |
Osi Pharm Inc |
Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
|
|
MY179032A
(en)
*
|
2004-10-25 |
2020-10-26 |
Cancer Research Tech Ltd |
Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
|
|
WO2006091450A1
(en)
|
2005-02-18 |
2006-08-31 |
Lexicon Genetics Incorporated |
4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
|
|
CA2598956A1
(en)
*
|
2005-02-24 |
2006-08-31 |
Pfizer Products Inc. |
Bicyclic heteroaromatic derivatives useful as anticancer agents
|
|
EP2100618B1
(en)
|
2005-06-17 |
2014-02-12 |
ImClone LLC |
An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer
|
|
ES2370054T3
(es)
|
2005-08-24 |
2011-12-12 |
Bristol-Myers Squibb Company |
Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico.
|
|
US20080161320A1
(en)
*
|
2006-09-11 |
2008-07-03 |
Xiong Cai |
Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
|
|
SG174772A1
(en)
*
|
2006-09-11 |
2011-10-28 |
Curis Inc |
Multi-functional small molecules as anti-proliferative agents
|
|
US20080076750A1
(en)
*
|
2006-09-15 |
2008-03-27 |
Aslanian Robert G |
Azetidinone Derivatives and Methods of Use Thereof
|
|
US7884080B2
(en)
*
|
2006-09-15 |
2011-02-08 |
Schering Plough Corporation |
Azetidinone derivatives and methods of use thereof
|
|
WO2008033431A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
|
|
EP2247596A2
(en)
|
2008-01-11 |
2010-11-10 |
Natco Pharma Limited |
Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
|
|
DK2384326T3
(da)
|
2008-08-20 |
2014-05-05 |
Zoetis Llc |
Pyrrolo[2,3-d]pyrimidinforbindelser
|
|
CA2742986C
(en)
|
2008-11-07 |
2015-03-31 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
|
JP2012520893A
(ja)
|
2009-03-18 |
2012-09-10 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
|
|
WO2011053779A2
(en)
|
2009-10-30 |
2011-05-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
|
EP2510110A1
(en)
|
2009-11-13 |
2012-10-17 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
EP2468883A1
(en)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
|
EP2670244B1
(en)
*
|
2011-02-04 |
2018-04-11 |
Duquesne University of The Holy Spirit |
Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
|
|
EP2492688A1
(en)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molecular biomarkers for predicting response to antitumor treatment in lung cancer
|
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
GB201106870D0
(en)
|
2011-04-26 |
2011-06-01 |
Univ Belfast |
Marker
|
|
RU2614254C2
(ru)
|
2011-08-31 |
2017-03-24 |
Дженентек, Инк. |
Диагностические маркеры
|
|
KR20140066783A
(ko)
|
2011-09-30 |
2014-06-02 |
제넨테크, 인크. |
종양 또는 종양 세포에서의 상피 또는 중간엽 표현형 및 egfr 키나제 억제제에 대한 반응의 진단 메틸화 마커
|
|
US20140309229A1
(en)
|
2011-10-13 |
2014-10-16 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
|
MX2015002887A
(es)
*
|
2012-09-06 |
2015-07-06 |
Plexxikon Inc |
Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
|
|
AU2014223548A1
(en)
|
2013-02-26 |
2015-10-15 |
Triact Therapeutics, Inc. |
Cancer therapy
|
|
EP2976085A1
(en)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
|
WO2015035410A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutic, Inc. |
Cancer therapy
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
CA2969830A1
(en)
|
2014-12-24 |
2016-06-30 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
|
WO2018078143A1
(en)
|
2016-10-28 |
2018-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
|
|
CN110366550A
(zh)
|
2016-12-22 |
2019-10-22 |
美国安进公司 |
作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
|
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
|
EP3679040B1
(en)
|
2017-09-08 |
2022-08-03 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
|
MA52496A
(fr)
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
|
US11090304B2
(en)
|
2018-05-04 |
2021-08-17 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
JP7357644B2
(ja)
|
2018-06-11 |
2023-10-06 |
アムジエン・インコーポレーテツド |
がんを処置するためのｋｒａｓ ｇ１２ｃ阻害剤
|
|
EP3807276B1
(en)
|
2018-06-12 |
2025-12-10 |
Amgen Inc. |
Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
|
BR112021006407A8
(pt)
|
2018-10-04 |
2022-12-06 |
Inst Nat Sante Rech Med |
uso de inibidores do egfr para ceratodermas
|
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
|
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
|
|
AU2019384118B2
(en)
|
2018-11-19 |
2025-06-12 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
|
IL283639B2
(en)
|
2018-12-20 |
2024-06-01 |
Amgen Inc |
Kif18a inhibitors
|
|
EP3898616B1
(en)
|
2018-12-20 |
2024-10-02 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
|
ES2997190T3
(en)
|
2018-12-20 |
2025-02-14 |
Amgen Inc |
Heteroaryl amides useful as kif18a inhibitors
|
|
US12459932B2
(en)
|
2018-12-20 |
2025-11-04 |
Amgen Inc. |
KIF18A inhibitors
|
|
NL2022471B1
(en)
|
2019-01-29 |
2020-08-18 |
Vationpharma B V |
Solid state forms of oclacitinib
|
|
AU2020232616A1
(en)
|
2019-03-01 |
2021-09-09 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
JP7092935B2
(ja)
|
2019-05-21 |
2022-06-28 |
アムジエン・インコーポレーテツド |
固体形態
|
|
EP4007753B1
(en)
|
2019-08-02 |
2025-09-24 |
Amgen Inc. |
Kif18a inhibitors
|
|
CA3146693A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
CA3147276A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
|
AU2020369569A1
(en)
|
2019-10-24 |
2022-04-14 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
|
|
IL320513A
(en)
|
2019-11-04 |
2025-06-01 |
Revolution Medicines Inc |
RAS inhibitors
|
|
US11608346B2
(en)
|
2019-11-04 |
2023-03-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CR20220240A
(es)
|
2019-11-04 |
2022-08-03 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
CN114901662A
(zh)
|
2019-11-08 |
2022-08-12 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
|
TW202132271A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
|
|
BR112022009390A2
(pt)
|
2019-11-14 |
2022-08-09 |
Amgen Inc |
Síntese melhorada de composto inibidor de kras g12c
|
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
|
WO2021142026A1
(en)
|
2020-01-07 |
2021-07-15 |
Revolution Medicines, Inc. |
Shp2 inhibitor dosing and methods of treating cancer
|
|
EP4168002A1
(en)
|
2020-06-18 |
2023-04-26 |
Revolution Medicines, Inc. |
Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
|
|
CA3187757A1
(en)
|
2020-09-03 |
2022-03-24 |
Ethan AHLER |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
US11690915B2
(en)
|
2020-09-15 |
2023-07-04 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20240051956A1
(en)
|
2020-12-22 |
2024-02-15 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
CN118561952A
(zh)
|
2021-05-05 |
2024-08-30 |
锐新医药公司 |
Ras抑制剂
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
US20250282782A1
(en)
|
2021-12-17 |
2025-09-11 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
AU2023230882A1
(en)
|
2022-03-07 |
2024-08-22 |
Amgen Inc. |
A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile.
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
EP4601644A1
(en)
|
2022-10-14 |
2025-08-20 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
|
CR20250458A
(es)
|
2023-03-30 |
2025-11-21 |
Revolution Medicines Inc |
Composiciones para inducir la hidrólisis de ras gtp y sus usos
|
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
AU2024251341A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of a ras inhibitor
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|